The Texas Immuno-Oncology Biorepository, a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling.

Autor:	Kelly RJ; Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas., Whitsett TG; Neurogenomics Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona., Snipes GJ; Department of Pathology, Baylor University Medical Center, Dallas, Texas., Dobin SM; Department of Pathology, Baylor Scott & White Medical Center - Temple, Temple, Texas., Finholt J; Baylor Scott & White Research Institute, Dallas, Texas., Settele N; Baylor Scott & White Research Institute, Dallas, Texas., Priest EL; Baylor Scott & White Research Institute, Dallas, Texas., Youens K; Department of Pathology, Baylor University Medical Center, Dallas, Texas., Wallace LB; Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas.; Texas A&M Health Science Center, Dallas, Texas., Schwartz G; Department of Thoracic Surgery, Baylor University Medical Center, Dallas, Texas., Wong L; Texas A&M Health Science Center, Dallas, Texas.; Department of Hematology and Medical Oncology, Baylor Scott & White Medical Center - Temple, Temple, Texas., Henderson SM; Baylor Scott & White Vasicek Cancer Treatment Center - Temple, Temple, Texas., Gowan AC; Baylor Scott & White Vasicek Cancer Treatment Center - Temple, Temple, Texas., Fonkem E; Texas A&M Health Science Center, Dallas, Texas.; Department of Neurosurgery, Baylor Scott & White Medical Center - Temple, Temple, Texas., Juarez MI; Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas., Murray CE; Department of Hematology and Medical Oncology, Baylor Scott & White Medical Center - Temple, Temple, Texas.; Baylor Scott & White Cancer Center - Round Rock, Round Rock, Texas., Wu J; Department of Cardiac and Thoracic Surgery, Baylor Scott & White All Saints Medical Center, Fort Worth, Texas., Van Keuren-Jensen K; Neurogenomics Division, Translational Genomics Research Institute (TGen), Phoenix, Arizona., Pirrotte P; Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona., Highlander S; Pathogen and Microbiome Division, Translational Genomics Research Institute, Phoenix, Arizona., Contente T; Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona., Baker A; Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona., Victorino J; Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona., Berens ME; Cancer & Cell Biology Division, Translational Genomics Research Institute, Phoenix, Arizona.
Jazyk:	angličtina
Zdroj:	Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2022 Aug 26; Vol. 36 (1), pp. 1-7. Date of Electronic Publication: 2022 Aug 26 (Print Publication: 2023).
DOI:	10.1080/08998280.2022.2114129
Abstrakt:	A detailed understanding of the molecular and immunological changes that occur longitudinally across tumors exposed to immune checkpoint inhibitors is a significant knowledge gap in oncology. To address this unmet need, we created a statewide biospecimen collection and clinical informatics system to enable longitudinal tumor and immune profiling and to enhance translational research. The Texas Immuno-Oncology Biorepository (TIOB) consents patients to collect, process, store, and analyze serial biospecimens of tissue, blood, urine, and stool from a diverse population of over 100,000 cancer patients treated each year across the Baylor Scott & White Health system. Here we sought to demonstrate that these samples were fit for purpose with regard to downstream multi-omic assays. Plasma, urine, peripheral blood mononuclear cells, and stool samples from 11 enrolled patients were collected from various cancer types. RNA isolated from extracellular vesicles derived from plasma and urine was sufficient for transcriptomics. Peripheral blood mononuclear cells demonstrated excellent yield and viability. Ten of 11 stool samples produced RNA quality to enable microbiome characterization. Sample acquisition and processing methods are known to impact sample quality and performance. We demonstrate that consistent acquisition methodology, sample preparation, and sample storage employed by the TIOB can produce high-quality specimens, suited for employment in a wide array of multi-omic platforms, enabling comprehensive immune and molecular profiling. Competing Interests: Dr. Kelly has received institutional research support from Bristol Myers Squibb and Eli Lilly and has served on advisory boards for BMS, Merck, EMD Serono, Astra Zeneca, Daiichi Sankyo, Eisai, Astellas, Ipsen, Novartis, Takeda, Novocure, and Eli Lilly. The other authors have no conflicts to disclose. (Copyright © 2022 Baylor University Medical Center.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu